PCSK9 Inhibitors – Does the Benefit Outweigh the Cost?

The results of the GAUSS-3 trial were recently presented at the American College of Cardiology 65th Scientific Session & Expo and were published online in the Journal of the American Medical Association. How did the PCSK9 inhibitor perform among patients with statin intolerance? Was it found to be cost effective? Read more here. (Source: First Report Managed Care, 4/4/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
Medical Diagnostics: leveraging new opportunities from AI… 01/16/2020